SeeThruEquity Issues Valuation Update on BioSig Technologies

SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, announced it has issued an update note on BioSig Technologies (OTCQB:BSGM).
As quoted in the press release:

Hansen acquired for $80 million and is a close comp for BioSig: Based in Mountain View, CA, Hanson Medical was the first company listed on our peer valuation analysis when we initiated coverage of BioSig on February 17, 2016, and while there is no perfect comp for BioSig, we do think the transaction is relevant and that it reiterates the strategic value in the space. Like BioSig, Hansen Medical is focused on achieving better patient outcomes for cardiac arrhythmia. Hansen’s intravascular robotics enable more accurate and controlled catheter placement in order to improve patient outcomes for cardiac arrhythmia and endovascular procedures with its flagship Magellan™ Robotic System. Clearly the company is well-aligned and potentially complementary with BioSig, whose Flagship PURE EP™ System is intended to improve outcomes for patients with complex cardiac arrhythmias through complex real-time analysis of electrical activity in the heart to better identify the cause and nature of arrhythmias to drastically improve the process of finding catheter ablation targets – areas of tissue to destroy that otherwise create a cardiac arrhythmia.
We have been encouraged by the progress made by BioSig since our initiation of coverage on February 17, 2016, and note that shares have risen by 51% since that time. The recent acquisition of peer company Hansen Medicine highlights a key point made in our initiation of BioSig, which is the strategic value in the space to larger medical device payers as well as the history of significant M&A. We continue to like BioSig and the opportunities it is targeting in the growing $3.5 billion electrophysiology (EP) market. We maintain our price target of $3.53 for BioSig, which , if achieved, represents potential upside of 130.7% from the recent price of $1.37 on March 23, 2016.

Connect with BioSig Technologies (OTCQB:BSGM) to receive an Investor Presentation.